Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE SkelRegen, LLC
WEST CHESTER, Pa., Jan. 7, 2014 /PRNewswire/ -- SkelRegen, LLC, the leader in small molecule musculoskeletal tissue regeneration and the first to identify multiple small molecules that are osteoinductive and target different aspects of the skeletal tissue formation pathway, today announced an addition to its executive management team. Todd F. La Neve, J.D. will assume the role of SkelRegen CEO and Stephen R. La Neve will continue to serve as co-founder and director.
Involved since the inception of SkelRegen, Todd La Neve brings more than 20 years' experience in providing strategic direction and growth for businesses. He is a recognized legal expert and holds the prestigious Martindale-Hubbell® "A/V" rating for legal skill and ethical standards. Todd is also a founding member of Circularis, LLC, a consulting firm focused on business improvement and optimization in healthcare and other companies. As CEO of SkelRegen, he will focus on continued platform development across multiple families of small molecules as progression continues toward clinical trials.
Former SkelRegen CEO, Steve La Neve was recently appointed CEO of ETEX, where he brings 30+ years' of health care experience, leadership and success. Steve will continue to have a key governance role with the SkelRegen team as co-founder and director, and will assist with broad strategic and financial direction setting for the company.
"Todd's wealth of experience that includes legal expertise and strategic business development has always been a valued asset to SkelRegen, and we are pleased now to have him officially in the role of CEO," said Dr. Scott Boden, SkelRegen's co-founder and chief medical and technology officer. "We are also delighted that Steve La Neve will continue to be part of SkelRegen and we look forward to the potential synergies his new position with ETEX will bring to our efforts."
Dr. Scott Boden will continue in his role as co-founder and chief medical, science and technology officer. Dr. Boden is also a tenured Professor of Orthopaedic Surgery at the Emory University School of Medicine and serves as the Director of the Emory Orthopaedics & Spine Center, Vice Chair of Orthopaedics, CMO/CQO of The Emory University Orthopaedics & Spine Hospital, and Emory Healthcare Physician Director of Strategy and Development for Orthopaedics & Spine Programs. He is also the Clinical Director of the Whitesides Orthopaedic Research Laboratory. John M. Wozney, Ph.D. will continue in his role as director of scientific affairs and co-owner.
SkelRegen, LLC was formed in the state of Delaware in September 2012. The company maintains its headquarters in West Chester, PA. For more information on the company, its products, or investment opportunities, please visit the company's website at SkelRegen.com or call the company's media contact directly.
©2012 PR Newswire. All Rights Reserved.